10-Q quarterly report · filed Nov 3, 2026

AbbVie Inc (ABBV) Q3 2026 10-Q Quarterly Report

Short answer

AbbVie Inc (ABBV) filed its Q3 2026 10-Q quarterly report on Nov 3, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $17.4B (up 10.3% year over year) with net income of $4.2B.

Q3 2026 key financials · XBRL

Revenue
$17.4B
+10.3% YoY · +2.4% QoQ
Net income
$4.2B
+2167.7% YoY · +16.7% QoQ
Operating margin
36.0%
EPS (diluted)
$2.37
+2270.0% YoY · +16.7% QoQ

Source: XBRL data from the AbbVie Inc (ABBV) Q3 2026 10-Q on SEC EDGAR. USD.

AbbVie Inc Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Quarterly revenue $17,404M, up 10.3% YoY from $15,776M
  • Gross margin $13,119M, 75.4% vs 66.4% YoY
  • Best performer: Skyrizi revenue $5,776M, up 22.7%; worst: Humira, down 31.2%
  • Operating cash flow $14,871M, up from $13,812M; acquisitions used $10.6B
  • Headwinds: biosimilar competition, drug pricing reform, tariffs and global macroeconomic uncertainty

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other AbbVie Inc quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.